Characterization of a novel <i>Leishmania</i> antigen containing a repetitive domain and its potential use as a prophylactic and therapeutic vaccine.

ABSTRACT: Human visceral leishmaniasis (HVL) is the second most lethal tropical parasitic disease. Currently, no prophylactic or therapeutic vaccines exist for HVL. Thus, the development of an efficacious vaccine is still needed. We previously performed an immunoproteomics analysis on Leishmania amazonensis parasite extracts to identify immunodominant antigens recognized by the sera of vaccinated and protected mice. Among the identified antigens, we discovered a novel, previously unstudied repetitive protein, initially annotated in Leishmania genomes as a kinetoplast-associated protein-like protein from Leishmania infantum (LinKAP), containing conserved domains (trichohyalin-plectin-homology [TPH] and TolA) that are associated with other mitochondrial proteins. LinKAP sequences

SUBMITTER: de Oliveira B 

PROVIDER: S-EPMC12108087 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature